{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = (1S,3aS,3bR,10aR,10bS,12aS)-1,6,6,10a,12a-Pentamethyl-2,3,3a,3b,4,6,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d][1,2]oxazol-1-ol
| image = Azastene.svg
| width = 250px

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 13074-00-5
| CAS_supplemental = 
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 11725766
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 9900482
| UNII = 1XA84ITL1H
| KEGG = 
| ChEBI = 
| ChEMBL = 2103987

<!--Chemical data-->
| C = 23 | H = 33 | N = 1 | O = 2
| molecular_weight = 355.522 g/mol
| SMILES = C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC=C4[C@@]3(CC5=C(C4(C)C)ON=C5)C
| StdInChI_Ref = 
| StdInChI = 1S/C23H33NO2/c1-20(2)18-7-6-15-16(21(18,3)12-14-13-24-26-19(14)20)8-10-22(4)17(15)9-11-23(22,5)25/h7,13,15-17,25H,6,8-12H2,1-5H3/t15-,16+,17+,21-,22+,23+/m1/s1
| StdInChIKey_Ref = 
| StdInChIKey = AXLOCHLTNQDFFS-BESJYZOMSA-N
| synonyms = WIN-17625; 4,4,17α-Trimethylandrosta-2,5-dieno(2,3-d)isoxazol-17β-ol
}}

'''Azastene''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (developmental code name '''WIN-17625''') is a [[steroidogenesis inhibitor]] described as a [[hormonal contraceptive|contraceptive]] and [[abortifacient]] which was never marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA113|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=113–}}</ref> It acts as a [[competitive inhibitor]] of [[3β-hydroxysteroid dehydrogenase]] ([[IC50|IC<sub>50</sub>]] = 1&nbsp;μM), and thereby inhibiting the [[biosynthesis|formation]] of [[progesterone]], [[corticosteroid]]s, [[androgen]]s, and [[estrogen]]s.<ref name="RunnebaumRabe2012">{{cite book|author1=B. Runnebaum|author2=T. Rabe|author3=L. Kiesel|title=Future Aspects in Contraception: Proceeding of an International Symposium held in Heidelberg, 5–8 September 1984 Part 1 Male Contraception|url=https://books.google.com/books?id=GX2oBgAAQBAJ&pg=PA74|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-009-4910-2|pages=74–}}</ref><ref name="Elsevier1991">{{cite book|title=Progress in Medicinal Chemistry|url=https://books.google.com/books?id=DcFBqjf7J08C&pg=PA259|date=5 April 1991|publisher=Elsevier|isbn=978-0-08-086276-7|pages=259–}}</ref>

==Synthesis==
[[File:Azastene synthesis.png|thumb|center|500px|Azastene synthesis:<ref>Gordon O. Potts, [[Sterling Drug]] Inc. {{US Patent|3,966,926}} (1976).</ref>]]

One synthesis of this compound involves initial alkylation of methyl testosterone by means of strong base and methyl iodide to afford the 4,4-dimethyl derivative. Formylation with alkoxide and [[methyl formate]] leads to the 2-hydroxymethyl derivative. Reaction of this last with [[hydroxylamine]] leads to formation of an isoxazole ring. There is then obtained azastene.

==See also==
* [[Cyanoketone]]

==References==
{{Reflist|2}}


[[Category:3β-Hydroxysteroid dehydrogenase inhibitors]]
[[Category:Androstanes]]
[[Category:Isoxazoles]]


{{steroid-stub}}